Optimize Neurology Prior Authorizations with Magellan Healthcare

Klivira optimizes prior authorization workflows for **neurology Magellan Healthcare** plans, addressing the complex requirements of high-cost specialty drugs and advanced diagnostics.

Revenue cycle directors and prior authorization coordinators in neurology practices face significant administrative burdens managing complex PA requirements, particularly for specialty medications and advanced imaging. Navigating Magellan Healthcare's specific utilization management criteria for neurological conditions demands precision and efficiency to minimize delays and denials.

The Intersection of Neurology and Magellan Healthcare Utilization Management

Magellan Healthcare, a Centene company, administers utilization management for a broad spectrum of neurological services, from high-efficacy MS disease-modifying therapies (DMTs) to CGRP migraine biologics and advanced imaging. Practices must align with Magellan's specific clinical criteria, often derived from AAN Practice Guidelines, to ensure timely approval for critical patient care.

Key Neurology PA Triggers for Magellan Healthcare Plans

  • MS disease-modifying therapies (e.g., ocrelizumab, natalizumab, fingolimod biosimilars)
  • CGRP monoclonal antibodies for migraine prevention (e.g., erenumab, galcanezumab, eptinezumab)
  • Alzheimer's anti-amyloid antibodies (e.g., lecanemab, donanemab) requiring amyloid confirmation
  • Advanced imaging, including brain MRI, MR angiography, and amyloid PET scans
  • Botox for chronic migraine, spasticity, or dystonia
  • Neuromodulation procedures (e.g., Deep Brain Stimulation, Vagus Nerve Stimulation)

Navigating Magellan's Documentation and Clinical Criteria for Neurology

Magellan Healthcare's UM often requires detailed clinical documentation, such as McDonald criteria for MS, amyloid confirmation for Alzheimer's therapies, or comprehensive headache diaries for CGRP biologics. Common denial reasons include incomplete step therapy documentation for MS DMTs or CGRP agents, or insufficient evidence for chronic migraine criteria for Botox, aligning with NCD/LCD standards.

EMR and Payer Workflow Touchpoints for Magellan Neurology PAs

  • Order types for specialty drugs within EMR systems (e.g., Epic, Cerner)
  • Submission via Magellan's provider portal or X12 278 transactions
  • Integration of clinical templates for specific diagnoses (e.g., MS, AD, epilepsy)
  • Automated retrieval of patient demographics and clinical notes (ePHI)
  • Tracking of periodic re-authorization for chronic neurology treatments and MRI monitoring

Klivira's Solution for Magellan Healthcare Neurology Prior Authorizations

Klivira automates the submission process for **neurology Magellan Healthcare** PAs, leveraging intelligent workflows to meet specific documentation requirements. Our platform is designed to navigate complex step-therapy protocols for MS DMTs and CGRP biologics, and to streamline the detailed biomarker and imaging documentation needed for Alzheimer's anti-amyloid therapies, aligning with AAN guidelines.

Enhancing Efficiency and Reducing Administrative Burden

By integrating directly with EMRs via SMART on FHIR and connecting to payer portals, Klivira reduces manual data entry and accelerates turnaround times for neurology PAs with Magellan. This allows PA coordinators to focus on patient care rather than repetitive administrative tasks, improving operational efficiency and patient access to critical neurological treatments.

Frequently asked questions

How does Klivira handle Magellan's step therapy requirements for MS DMTs?

Klivira incorporates AAN-guideline-aware step-therapy logic, automating the documentation and submission process to demonstrate compliance with Magellan Healthcare's specific requirements for MS disease-modifying therapies, minimizing delays.

What specific documentation does Klivira automate for Alzheimer's anti-amyloid PAs with Magellan?

Klivira streamlines the collection and submission of critical documentation for Alzheimer's anti-amyloid therapies, including amyloid confirmation (PET or CSF), MRI for ARIA screening, and ApoE genotype results, essential for Magellan Healthcare approvals.

Can Klivira integrate with our EMR to submit neurology PAs to Magellan?

Yes, Klivira integrates with major EMR systems using SMART on FHIR, enabling seamless data flow for patient demographics and clinical notes, automating the submission of neurology PAs to Magellan Healthcare directly from your existing workflows.

Does Klivira support periodic re-authorization for chronic neurology treatments with Magellan?

Absolutely. Klivira's platform includes robust workflows for managing periodic re-authorizations, ensuring continuous coverage for chronic neurology treatments like MS DMTs, CGRP biologics, and associated MRI monitoring, as required by Magellan Healthcare.

Which neurological conditions see the most benefit from Klivira's Magellan PA automation?

Our automation is particularly beneficial for high-volume, complex PAs in neurology, including treatments for Multiple Sclerosis, chronic migraine, Alzheimer's disease, epilepsy, and advanced imaging, which frequently trigger Magellan Healthcare's utilization management.

Related coverage

Other neurology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo